Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells

• Published in: Cancers Vol. 14; no. 6; p. 1551
• Main Authors: Deshors, Pauline, Arnauduc, Florent, Boëlle, Betty, Cohen-Jonathan Moyal, Elizabeth, Courtade-Saïdi, Monique, Evrard, Solène M
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18-03-2022; MDPI
• Subjects: Angiogenesis; Blood vessels; Brain cancer; Brain tumors; Chemotherapy; Endothelial cells; Experiments; Glioblastoma; I.R. radiation; Kinases; Nervous system; Prognosis; Radiation therapy; Signal transduction; Stem cells; Tumors; Xenografts; France; United States > US; transdifferentiation; glioblastoma stem-like cells; ionising radiation; glioblastoma; regorafenib; tumour-derived endothelial cells
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14061551

Glioblastomas (GBM) are aggressive brain tumours with a poor prognosis despite heavy therapy that combines surgical resection and radio-chemotherapy. The presence of a subpopulation of GBM stem cells (GSC) contributes to tumour aggressiveness, resistance and recurrence. Moreover, GBM are characterised by abnormal, abundant vascularisation. Previous studies have shown that GSC are directly involved in new vessel formation via their transdifferentiation into tumour-derived endothelial cells (TDEC) and that irradiation (IR) potentiates the pro-angiogenic capacity of TDEC via the Tie2 signalling pathway. We therefore investigated the impact of regorafenib, a multikinase inhibitor with anti-angiogenic and anti-tumourigenic activity, on GSC and TDEC obtained from irradiated GSC (TDEC IR+) or non-irradiated GSC (TDEC). Regorafenib significantly decreases GSC neurosphere formation in vitro and inhibits tumour formation in the orthotopic xenograft model. Regorafenib also inhibits transdifferentiation by decreasing CD31 expression, CD31+ cell count, pseudotube formation in vitro and the formation of functional blood vessels in vivo of TDEC and TDEC IR+. All of these results confirm that regorafenib clearly impacts GSC tumour formation and transdifferentiation and may therefore be a promising therapeutic option in combination with chemo/radiotherapy for the treatment of highly aggressive brain tumours.